Clinical Trial Update: Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing cabazitaxel with or without carboplatin to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer; recruitment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Jevtana (cabazitaxel)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING